摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide | 1016950-52-9

中文名称
——
中文别名
——
英文名称
N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide
英文别名
N-[7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]-2-phenylacetamide
N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide化学式
CAS
1016950-52-9
化学式
C26H29NO8
mdl
——
分子量
483.518
InChiKey
VLRLEAJZDNBBRG-KWLZBDKBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    35
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    124
  • 氢给体数:
    3
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide 生成 Benzyl 2-(8-methyl-7-(1-methylpiperidin-3-yloxy)-2-oxo-2H-chromen-3-ylamino)-2-oxoacetate
    参考文献:
    名称:
    NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    摘要:
    新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病(ADPKD)中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法,包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平,或其组合。此外,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平,或其组合。
    公开号:
    US20110082098A1
  • 作为产物:
    描述:
    N-(7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide三乙胺 作用下, 以 甲醇 为溶剂, 反应 14.0h, 以87%的产率得到N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-2-phenylacetamide
    参考文献:
    名称:
    Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines
    摘要:
    Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at similar to 700 mu M. As a result of these studies, several analogues of the coumarin family of antibiotics have been reported and shown to exhibit increased Hsp90 inhibitory activity; however, the monomeric species lacked the ability to manifest anti-proliferative activity against cancer cell lines at concentrations tested. In an effort to develop more efficacious compounds that produce growth inhibitory activity against cancer cell lines, structure-activity relationships; were investigated surrounding the prenylated benzamide side chain of the natural product. Results obtained from these studies have produced the first novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
    DOI:
    10.1021/jo702191a
点击查看最新优质反应信息

文献信息

  • Heat shock protein 90 inhibitor dosing methods
    申请人:Rajewski Roger A.
    公开号:US20100022635A1
    公开(公告)日:2010-01-28
    The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days.
    该披露提供了新型的Hsp90抑制剂用于治疗或预防神经退行性疾病、自身免疫疾病或癌症的剂量方案。该方法涉及向需要治疗的受试者施用至少一种Hsp90抑制剂的治疗有效剂量的一个或多个剂量,以使在大约7天的时间内不会施用超过单一剂量。
  • NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES
    申请人:Blagg Brian S. J.
    公开号:US20120252745A1
    公开(公告)日:2012-10-04
    The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
    本公开提供了具有替代noviose的诺维菌素类似物,其在癌症治疗中作为Hsp90抑制剂是有用的。
  • Novobiocin Analogues Having Modified Sugar Moieties
    申请人:Blagg Brian
    公开号:US20090163709A1
    公开(公告)日:2009-06-25
    Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.
    诺伐霉素类似物在癌症、神经保护和自身免疫性疾病的治疗中作为Hsp90抑制剂有用。
  • Novobiocin Analogues
    申请人:Blagg Brian
    公开号:US20090187014A1
    公开(公告)日:2009-07-23
    Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders, as well as cancer.
    Novobiocin类似物和含有这些化合物的药物组合物,可用于治疗和/或预防神经退行性疾病、自身免疫性疾病以及癌症。
  • US8212012B2
    申请人:——
    公开号:US8212012B2
    公开(公告)日:2012-07-03
查看更多